Dyne Therapeutics, Inc. DYN Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dyne Therapeutics, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dyne Therapeutics, Inc.'s accrued expenses and other liabilities?
- Dyne Therapeutics, Inc. (DYN) reported accrued expenses and other liabilities of $29.21M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Dyne Therapeutics, Inc.'s accrued expenses and other liabilities increased by 34.3% year-over-year, from $21.75M to $29.21M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s accrued expenses and other liabilities has grown at a 37.9% compound annual growth rate (CAGR), from $7.53M to $37.55M.